Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial

Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial

Background: Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit. Objectives: Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA)....

Full description

Saved in:
Bibliographic Details
Main Authors: Stefan Siebert, Georg Schett, Siba P. Raychaudhuri, Monica Guma, Warner Chen, Sheng Gao, Soumya D. Chakravarty, Frederic Lavie, Proton Rahman
Format: Article
Language:English
Published: SAGE Publishing 2024-10-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X241283536
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items